Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 08/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. CYTK, VKTX, TGTX, KRYS, ACAD, PCVX, AAPG, ACLX, ADMA, and ZLABShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), Arcellx (ACLX), ADMA Biologics (ADMA), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Its Competitors Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Vaxcyte Ascentage Pharma Group International Arcellx ADMA Biologics Zai Lab Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment. Which has more risk & volatility, CALT or CYTK? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Do analysts prefer CALT or CYTK? Cytokinetics has a consensus target price of $71.58, suggesting a potential upside of 86.71%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts plainly believe Cytokinetics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93 Does the media refer more to CALT or CYTK? In the previous week, Cytokinetics had 16 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 16 mentions for Cytokinetics and 0 mentions for Calliditas Therapeutics AB (publ). Cytokinetics' average media sentiment score of 0.45 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Cytokinetics is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Cytokinetics Neutral Which has preferable valuation & earnings, CALT or CYTK? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Cytokinetics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Cytokinetics$18.47M248.39-$589.53M-$5.10-7.52 Do institutionals & insiders hold more shares of CALT or CYTK? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 2.7% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is CALT or CYTK more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Cytokinetics' net margin of -707.17%. Cytokinetics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Cytokinetics -707.17%N/A -45.52% SummaryCytokinetics beats Calliditas Therapeutics AB (publ) on 10 of the 17 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$835.44M$5.83B$9.73BDividend YieldN/A4.84%3.84%4.09%P/E Ratio-21.621.1831.1625.99Price / Sales0.7426.52474.86122.97Price / CashN/A19.5637.1558.38Price / Book37.746.639.116.38Net Income-$43.96M-$4.94M$3.26B$265.56M7 Day PerformanceN/A0.87%2.06%1.89%1 Month PerformanceN/A2.76%5.08%1.23%1 Year Performance-0.74%11.86%31.26%21.10% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180CYTKCytokinetics3.6123 of 5 stars$38.95+0.7%$71.58+83.8%-32.8%$4.63B$18.47M-7.64250News CoverageVKTXViking Therapeutics4.0237 of 5 stars$42.09+5.1%$86.92+106.5%-60.4%$4.50BN/A-27.5120Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3598 of 5 stars$27.73-1.2%$46.25+66.8%+14.8%$4.46B$454.07M74.95290Positive NewsKRYSKrystal Biotech4.7396 of 5 stars$146.30-2.6%$210.75+44.1%-27.7%$4.35B$359.21M29.74210News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals3.9511 of 5 stars$25.06-1.1%$28.88+15.2%+55.6%$4.27B$1.02B18.84510Insider TradePCVXVaxcyte2.5594 of 5 stars$32.09-1.9%$136.50+325.4%-60.0%$4.25BN/A-7.81160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$47.49+5.6%N/AN/A$4.18B$134.35M0.00600News CoverageACLXArcellx2.1831 of 5 stars$71.82-3.1%$114.31+59.2%+7.7%$4.11B$107.94M-21.0080Positive NewsADMAADMA Biologics4.4028 of 5 stars$17.63+3.8%$27.67+56.9%-4.1%$4.05B$474.17M20.50530Positive NewsZLABZai Lab2.8362 of 5 stars$35.69-0.1%$57.22+60.3%+94.2%$3.97B$398.99M-17.501,869News CoverageInsider Trade Related Companies and Tools Related Companies Cytokinetics Alternatives Viking Therapeutics Alternatives TG Therapeutics Alternatives Krystal Biotech Alternatives ACADIA Pharmaceuticals Alternatives Vaxcyte Alternatives Ascentage Pharma Group International Alternatives Arcellx Alternatives ADMA Biologics Alternatives Zai Lab Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access